使用钠-葡萄糖共转运蛋白抑制剂的1型糖尿病患者毛细血管酮体水平与未来酮症酸中毒风险
本研究基于恩格列净组1型糖尿病试验数据,分析每周空腹毛细血管酮体水平与后续 adjudicated 糖尿病酮症酸中毒(DKA)或严重酮症的关系。结果显示,结局发生前28天内治疗中最大酮体水平高于无结局者,ROC曲线下面积为0.76(95% CI 0.71-0.82);最大酮体≥0.8 mmol/L的灵敏度为66.0%、特异度为79.6%、诊断比值比为7.6。作者认为常规酮体监测可能代表DKA减轻策略,并提示连续酮体监测的潜在阈值。
要点
- 结局发生前28天内的治疗中最大酮体水平高于无结局者(ROC曲线下面积0.76,95% CI 0.71-0.82)。
- 最大酮体≥0.8 mmol/L预测结局的灵敏度66.0%、特异度79.6%、诊断比值比7.6。
- 作者认为常规毛细血管酮体监测可能代表DKA减轻策略,并提示连续酮体监测的潜在阈值。
核心结论
- 作者认为,在使用SGLTi的T1D患者中常规监测毛细血管酮体水平可能代表一种DKA减轻策略,并提示连续酮体监测的潜在阈值。
研究设计与样本
- 研究分析了1型糖尿病试验中分配至恩格列净组的参与者既往收集的数据,该试验包含每周空腹酮体水平。
- 在6-12个月内,酮体水平被细分为28天时段,结局为后续 adjudicated DKA 或严重酮症。
- 共纳入1194名参与者,其中325名发生了49例DKA和568例严重酮症事件。
主要发现
- 结局发生前28天内的治疗中最大酮体水平高于无结局者的水平,ROC曲线下面积为0.76(95% CI 0.71-0.82)。
- 最大酮体水平≥0.8 mmol/L的灵敏度为66.0%,特异度为79.6%,诊断比值比为7.6。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine if routine capillary blood ketone testing on well days predicts future diabetic ketoacidosis (DKA) in type 1 diabetes (T1D) using sodium-glucose cotransporter inhibitors (SGLTi). RESEARCH DESIGN AND METHODS: We examined previously collected data from empagliflozin-assigned participants in a T1D trial that included weekly fasted ketone levels. Over 6-12 months, ketone levels were subdivided into 28-day periods, and the outcome was subsequent adjudicated DKA or severe ketosis. RESULTS: Among 1,194 participants, 325 had 49 DKA and 568 severe ketosis events. On-treatment maximum ketone levels were higher in the 28 days before an outcome compared with levels in those without an outcome, with area under receiver operating characteristic curve of 0.76 (95% CI 0.71-0.82). Maximum ketone level ≥0.8 mmol/L had sensitivity of 66.0%, specificity of 79.6%, and diagnostic odds ratio of 7.6. CONCLUSIONS: Routine surveillance of capillary ketone levels in T1D using SGLTi may represent a DKA mitigation strategy and implies a potential threshold for continuous ketone monitoring.
引用
- Bapat P, Dhaliwal S, Song C, et al. Capillary Ketone Level and Future Ketoacidosis Risk in Patients With Type 1 Diabetes Using Sodium-Glucose Cotransporter Inhibitors. Diabetes Care. 2025. PMID: 40267366. doi:10.2337/dc25-0125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。